TMS Solutions Cyprus Greece

26/11/2025

Thinking About Adding TMS? Join Our Dec 4 Education Workflow Webinar December 4: Magstim Horizon 3.0 with StimGuide Pro

Contact us today to join this live TMS education webinar demonstrating the Magstim Horizon 3.0 with StimGuide Pro. Learn key steps to find the TMS motor threshold and an overview of treatment options.

Designed with an intuitive, user-friendly interface and treatment protocols, which provide clinicians and researchers with the flexibility to tailor stimulation parameters to individual patient needs, ensuring optimal treatment outcomes.

Horizon 3.0 is FDA cleared for clinical treatment of MDD, OCD, Anxious Depression and Adolescent MDD.

HORIZON 3.0 ADVANTAGES
• No pay-per-use plans.
• Intuitive preset clinical workflows.
• Customizable treatments.
• Treatment accuracy.
• Powerful data analytics.
• Correct and consistent dosage amounts with no pulse decay.
• Magstim’s air-cooled coil technology eliminates downtime
and extra expenses.
• No hidden costs.

13/11/2025

FDA Clears Magstim Magnetic Stimulation for Pain Therapy

FDA CLEARS MAGSTIM MAGNETIC STIMULATION FOR CHRONIC PAIN TREATMENT

Landmark clearance opens access to non-drug, non-invasive pain relief for millions

Millions of people living with chronic pain now have a clinically proven, non-invasive, and drug-free treatment option. The U.S. Food and Drug Administration has cleared Magstim Magnetic Stimulation for the treatment of chronic pain*, providing a validated therapy that directly targets neural pathways involved in pain processing and has already improved patient outcomes worldwide.

Magstim Magnetic Stimulation modulates neural pathways involved in pain
perception, helping patients experience reduced pain intensity, improved physical function, and enhanced quality of life. This is a tested, proven technology that empowers physicians and clinicians to treat pain at its source.

26/09/2025

EGI GES 500 - EEG System Product Launch

Seeing the Brain Like Never Before: EGI Launches the GES 500

For more than three decades, EGI has set the gold standard in high-density EEG. Now, with the GES 500, we’re redefining what’s possible in brain research and non-invasive stimulation.
The GES 500 isn’t just an amplifier—it’s an intelligent platform designed to streamline workflows, improve signal quality and integrate with Magstim TMS. Its future-ready architecture supports AI and machine learning applications, paving the way for real-time closed-loop research and advanced Neurotechnologies

https://www.youtube.com/watch?v=4zeHMzhgHUY

Contact us to learn more about available options and pricing.

Seeing the Brain Like Never Before: EGI Launches the GES 500 For more than three decades, EGI has set the gold standard in high-density EEG. Now, with the G...

05/09/2025

Unlock new possibilities with the NEW Magstim Rapid TMS system.
Your gateway to groundbreaking discoveries.
Transcranial Magnetic Stimulation research solutions.

Get in touch with us for more options and pricing details.

Contact us to learn more about available options and pricing.

17/07/2025

TMS Webinar Invite: Magstim Rapid System Workflow & Research Applications July 30

FDA CLEARS UPDATED MAGSTIM RAPID TMS RESEARCH SYSTEM

Cleared for research and clinical applications
and FDA cleared in the U.S. for the treatment of pain*

Top-Cited Research System Enhanced for Next-Generation TMS

Magstim’s Rapid series has long been the go-to choice for researchers across the globe, cited in thousands of peer reviewed studies. Now, with enhanced configurability, performance, and connectivity.

10/07/2025

Just Launched: FDA Clears New Magstim Rapid TMS System

We’re excited to release the next generation in TMS research—the New Magstim Rapid TMS system.

• Now FDA for stimulation of peripheral nerves in pain relief
• Intuitive, Windows-based software
• Multiple configurations to fit your research
• Enhanced MEP signal quality
• Improved data management
• Seamless integration with EEG, EMG & more

Trusted by researchers worldwide, the updated Rapid is built to support the future of neuromodulation.

Unlock new possibilities. Discover the new Rapid.
Book your free virtual demonstration: magstim.com

https://youtu.be/Dgntcn3Pp7k

At Magstim, innovation never stands still, and neither should your research. We’re proud to announce the release of the new Magstim Rapid TMS System, a power...

24/06/2025

Webinar--TMS in Chronic Pain Management 2025

Watch this Magstim TMS webinar with Stevie Foglia, PhD, McMaster University and CEO of Neuro-Mod Inc., and Aimee Nelson, PhD, McMaster University, to learn new research for rTMS for chronic pain management. Drs. Foglia and Nelson will present the latest results in chronic pain management using TMS. This team also share insights on how practices throughout North America can get up and running.

Watch this Magstim TMS webinar with Stevie Foglia, PhD, McMaster University and CEO of Neuro-Mod Inc., and Aimee Nelson, PhD, McMaster University, to learn n...

28/05/2025

WEBINAR INVITE
Latest Research applications of TMS in chronic pain management:
New Research and Clinical Applications


THURSDAY MAY 29 2025
12 NOON EST

Join Stevie Foglia, PhD, McMaster University and CEO of Neuro-Mod Inc., and Aimee Nelson, PhD, McMaster University, to learn new research for rTMS for chronic pain management. Drs. Foglia and Nelson will present the latest results in chronic pain management using TMS. This team also share insights on how practices throughout North America can get up and running.

If you have not yet registered, please email us at sales@mkprosopsis.com

13/05/2025

NOW is the time to support adolescent patients with non-invasive, non-pharmacological TMS technology to improve care. The FDA cleared Magstim TMS for treatment of U.S. adolescent patients aged 15-21 for MDD. Practices using Magstim Horizon 3.0 and Inspire can begin treating adolescents immediately, following standard patient care protocols.*

29/04/2025

Does TMS really help depression?

TMS is an effective intervention for treatment-resistant depression and OCD. About 60% of people who didn't respond to other depression treatments respond to standard TMS protocols, and more than half of these patients stay in remission at six-month follow-up appointments after stopping TMS

26/03/2025

FDA CLEARS MAGSTIM HORIZON 3.0 TRANSCRANIAL MAGNETIC SYSTEMS FOR TREATMENT IN U.S. ADOLESCENT PATIENTS

If you’re interested in learning more about how the Magstim Horizon Transcranial Magnetic Stimulation Systems can support adolescent MDD treatment, we invite you to email us at sales@mkprosopsis.com

For Adults: Horizon 3.0 Transcranial Magnetic Stimulation Therapy Systems are indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, as well as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

For Adolescents: Horizon 3.0 Transcranial Magnetic Stimulation Therapy Systems are indicated as an adjunct for the treatment of MDD in adolescent patients (age 15-21).

20/03/2025

Treatment Medical Chairs for TMS therapies

Call us for more options and pricing